AbbVie Inc. (ABBV)
| Market Cap | 390.07B |
| Revenue (ttm) | 58.33B |
| Net Income (ttm) | 3.72B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.10 |
| PE Ratio | 105.14 |
| Forward PE | 16.72 |
| Dividend | $6.56 (2.97%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 5,257,791 |
| Open | 219.10 |
| Previous Close | 216.26 |
| Day's Range | 217.30 - 221.55 |
| 52-Week Range | 163.81 - 221.77 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 224.41 (+1.63%) |
| Earnings Date | Oct 29, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $224.41, which is an increase of 1.63% from the latest price.
News
Calls of the Day: Netflix, Disney, Walmart and AbbVie
The Investment Committee debate the latest Calls of the Day.
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
AbbVie Stock Hit a Record on ‘Big Win' for Blockbuster Drug. The Case for Buying In.
The company is dealing with declining sales of its former cash-cow drug Humira.
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord...
AbbVie in Settlement With Generic Drugmakers on Rinvoq
The biopharmaceutical company doesn't expect U.S. generic entry for the drug before 2037 now that it has settled litigation.
Why Is AbbVie Stock Trading Higher On Thursday?
AbbVie Inc. ABBV stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food an...
AbbVie: What's Happening With ABBV Stock?
AbbVie's stock is on the rise, and for good reason! The company just reached a major agreement with generic drug manufacturers to delay the release of a generic version of its blockbuster drug, Rinvoq...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, ac...
AbbVie Inc. (ABBV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Exec...
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Building on the brand's 20-year legacy and real-world experience, the original BOTOX® Cosmetic continues to be the most researched and requested product of its kind.1,2 BOTOX® Cosmetic is trusted by a...
Calls of the Day: Abbvie, Vertex, Veeva and Vistra
The Investment Committee discuss the latest Calls of the Day.
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Sept. 5, 2025 The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
AbbVie Announces Updated Results From Phase 2 EPCORE® NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Data presented at 13th Society of Hematologic Oncology (SOHO) Annual Meeting NORTH CHICAGO, Ill. , Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EP...
AbbVie to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NORTH CHICAGO, Ill. , Sept. 2, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025.
How To Invest $100,000 In A Near-Perfect Strategy Portfolio
Market timing is futile; a disciplined, diversified, and rules-based approach is essential for long-term investing success. A Near-Perfect Strategy portfolio aims for consistent income, growth, and lo...
AbbVie Smashes Earnings, Bets Big On Depression Drug Bretisilocin
President Trump's threats against Big Pharma do not prevent AbbVie shares from rising. AbbVie's strong financial results for the second quarter of 2025 were ensured by its two superstars, Rinvoq and S...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Best Dividend Aristocrats For September 2025
Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...
AbbVie: Plenty Of Positives
AbbVie has had a good August, with double digit MoM gains after seeing weakness for six months. Factors like an EU-US deal on pharmaceuticals, recent results, improved guidance, positive outcomes in ...
AbbVie Is A Top Biotech Pick
Q2 earnings results were strong for AbbVie as top line growth is at a historically high level and operating margin expanded due to SG&A efficiencies. The company's Rinvoq drug has new market potential...
AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion
AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion.
AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline
Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is...
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued...
AbbVie Investors Beware: Strong Growth Potential, Rising Risks
AbbVie has delivered strong total returns and dividend growth over time. Additionally, it enjoys strong growth prospects. However, it also faces significant uncertainty and risks.